Abstract
Published data on the association of vascular endothelial growth factor (VEGF) −1154G>A polymorphism with cancer risk is inconclusive. To derive a more precise estimation of association between VEGF −1154G>A polymorphism and the risk of cancer, we performed a meta-analysis of 7,071 cancer cases and 7,693 controls from 16 published case–control studies. Our meta-analysis didn’t reveal an association between VEGF −1154G>A polymorphism and overall cancer risk (GG vs. AA: OR: 1.08, 95% CI: 0.96–1.20; GA vs. AA: OR: 1.04, 95% CI: 0.93–1.17; recessive model: GG+GA vs. AA: OR: 1.06, 95% CI: 0.95–1.18; dominant model: GG vs. GA+AA, OR: 1.11, 95% CI: 1.00–1.24). Nevertheless, for non-Caucasians, GG homozygote may have higher cancer risk compared with either A carriers (OR: 1.58, 95% CI: 1.12–2.23) or AA homozygote (OR: 1.43, 95% CI: 1.17–1.76). No significant heterogeneity was detected except in the dominant model and “prostate cancer” subgroup analysis. More studies with larger samples are warranted to confirm these findings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shahbazi M, Fryer AA, Pravica V et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260–264
Pharoah PD, Tyrer J, Dunning AM et al (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42
Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22
Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173
Jin Q, Hemminki K, Enquist K et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653
Dassoulas K, Gazouli M, Rizos S et al (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48:563–569
Cacev T, Loncar B, Seiwerth S et al (2008) Vascular endothelial growth factor polymorphisms −1154 G/A and −460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol 27:569–574
McCarron SL, Edwards S, Evans PR et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372
Sfar S, Saad H, Mosbah F, Chouchane L (2010) Synergistic effect and VEGF/HSP70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome. Hum Immunol 71:377–382
Jacobs EJ, Hsing AW, Bain EB et al (2008) Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 17:972–977
Bruyere F, Hovens CM, Marson MN et al (2010) VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol 184:1273–1278
Ricketts C, Zeegers MP, Lubinski J, Maher ER (2009) Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS ONE 4:e6037
Li Y, Wang Y, Kang S et al (2010) Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer. Int J Gynecol Cancer 20:717–723
Tzanakis N, Gazouli M, Rallis G et al (2006) Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 94:624–630
Howell WM, Bateman AC, Turner SJ et al (2002) Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 3:229–232
Garcia-Closas M, Malats N, Real FX et al (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms, bladder cancer risk. PLoS Genet 3:e29
Unal ZN, Unal M, Bagdatoglu OT et al (2008) Genetic polymorphism of VEGF −1154 (A/G) in laryngeal squamous cell carcinoma. Arch Med Res 39:209–211
Xu B, Li JM, Tong N et al (2010) VEGFA +936C>T polymorphism and cancer risk: a meta-analysis. Cancer Genet Cytogenet 198:7–14
Cao C, Fang JJ, Ying T et al (2010) Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis. Arch Med Res 41:548–557
Liu L, Liu L, Zeng F et al (2011) Meta-analysis of the association between VEGF −634 G>C and risk of malignancy based on 23 case–control studies. J Cancer Res Clin Oncol 137:1027–1036
Cao C, Ying T, Fang JJ et al (2011) Polymorphism of vascular endothelial growth factor −2578C/A with cancer risk: evidence from 11263 subjects. Med Oncol 28(4):1169–1175
Xu B, Feng NH, Tong N et al (2010) VEGF −460C>T polymorphism and cancer risk: a meta-analysis. Med Oncol 27:1031–1036
Koukourakis MI, Papazoglou D, Giatromanolaki A et al (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293–298
Kawai Y, Sakano S, Korenaga Y et al (2007) Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52:1147–1155
Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672–4678
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hong, TT., Zhang, RX., Wu, XH. et al. Polymorphism of vascular endothelial growth factor −1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case–control studies. Mol Biol Rep 39, 5283–5289 (2012). https://doi.org/10.1007/s11033-011-1326-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-011-1326-9